Articles

Find an Article

Filter articles

Showing 11 to 20 of 692 results

Will the EU’s SPC manufacturing waiver weaken European pharma’s IP?

EU20-05-2020Paul Williams

Despite dire warnings by the US Chamber of Commerce, the impact of the EU’s SPC waiver won’t be known for years, says Paul Williams of Lewis Silkin.

Royalty Pharma: welcome clarity mixed with unwelcome ambiguity

EU15-05-2020Beatriz San Martin

The CJEU’s decision in Royalty Pharma has provided much-anticipated guidance on supplementary protection certificates but has left a lot of uncertainty. Was this the best the CJEU could come up with? Beatriz San Martin of Arnold & Porter reports.

Will Big Pharma get the bug for microbiome therapies?

Ireland, Japan, South Korea, UK, US06-05-2020Craig Thomson, Leena Contarino and Andrew Wells

The exciting field of microbiome therapeutics offers many opportunities for ‘Big Pharma’ players that are staring over the exclusivity cliff, say Craig Thomson, Leena Contarino and Andrew Wells of HGF.

Why things could get ugly over COVID-19 patents

30-04-2020Mark Engelman

Foreign patents protecting COVID-19 treatments may stall efforts to protect citizens, says Mark Engelman of Hardwicke chambers.

COVID-19: governments look to shield companies from IP enforcement

UK23-04-2020Andrew Pitts

The UK government’s indemnifying of ventilator manufacturers is a smart solution to potential licensing obstacles, says Andrew Pitts of Mewburn Ellis.

Patent pools: should rights owners give up their IP?

21-04-2020Rory O'Neill

Pressure is building on IP owners to offer up access to technology that could help fight COVID-19. Rory O'Neill looks at some of the implications for the patent system.

Compulsory licensing in Canada—revisited

Canada21-04-2020Daphne Lainson and Nancy Pei

New legislation has been enacted to help in the efforts to deal with the COVID-19 outbreak, as Daphne Lainson and Nancy Pei of Smart & Biggar report.

COVID-19: patent procurement and licensing

US31-03-2020Jonathan Tietz, Jason Mock, and Kristel Schorr

Jonathan Tietz, Jason Mock, and Kristel Schorr of Foley & Lardner offer their thoughts on patent procurement and licensing for COVID-19-related technologies.

UK patent system ‘no obstacle’ for ventilator production

UK19-03-2020Richard Fawcett

Richard Fawcett, senior associate at Powell Gilbert, outlines why the UK patent system poses no obstacle to the UK government’s rallying call for ventilator production amid the COVID-19 pandemic.

Broad Institute down (but not out) in the European fight over CRISPR IP

EU06-03-2020Claire Irvine

The search for clarity goes on as Broad gears up for another set of legal challenges, as Claire Irvine, partner at HGF, explains.

Showing 11 to 20 of 692 results

LSIPR